Effects of Prazosin in Patients with Benign Prostatic Obstruction

Abstract

Prazosin, a selective .alpha.-1-adrenoceptor blocker, was used in a double-blind crossover study in 20 men with benign prostatic obstruction. Maximum and average flow rates increased, and residual volume and obstructive symptoms were reduced. Voiding pressure parameters, bladder capacity and irritative symptoms did not change significantly. No side effects were noted. Prazosin seems to be an effective therapeutic alternative in patients with benign prostatic obstruction.